Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01,…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.22 | $-0.18 | $-0.24 |
| Estimado | $-0.21 | $-0.26 | $-0.26 | $-0.10 |
| Sorpresa | — | +15.4% | +30.8% | -140.0% |
| Métrica | CLLS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 100.0% | 57.4% | +42.6% |
| Operating Margin | -45.3% | -34.4% | -11.0% |
| Net Margin | -92.7% | -32.5% | -60.2% |
| FCF Margin | -57.3% | -12.6% | -44.7% |
| ROE | -89.0% | -39.2% | -49.9% |
| ROA | -20.8% | -30.9% | +10.1% |
| Current Ratio | — | 2.73 | — |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -20.8% | — |
| ✗Flujo de caja operativo positivo | −$39M | $23M |
| ✗Rentabilidad sobre activos al alza | -20.8% | -9.6% |
| ✓Caja operativa/activos supera al ROA | -12.1% | ROA -20.8% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | — | — |
| ✗Sin aumentar el nº de acciones | 100M | 91M |
| ✗Margen bruto al alza | 100.0% | 100.0% |
| ✓Rotación de activos al alza | 0.22 | 0.11 |
| Calidad del negocio | FY25 |
|---|---|
| ✗Margen FCF > 10 % | -57.3% |
| ✗ROCE > 10 % | -18.5% |
| ✓Ventas > 5 %/año (3 años) | 56.1% |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 131.4% |
Cellectis S.A. cotiza a 1.04 USD y tiene una capitalización bursátil de $105M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud